Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation

Mrinal M. Patnaik; Prateek A. Pophali; Terra L. Lasho; Christy M. Finke; Pedro Horna; Rhett P. Ketterling; Naseema Gangat; Abhishek A. Mangaonkar; Animesh Pardanani; Ayalew Tefferi

doi:10.3324/haematol.2018.208082

Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation

Mrinal M. Patnaik, Prateek A. Pophali, Terra L. Lasho, Christy M. Finke, Pedro Horna, Rhett P. Ketterling, Naseema Gangat, Abhishek A. Mangaonkar, Animesh Pardanani, Ayalew Tefferi

Research output: Contribution to journal › Letter › peer-review

11 Scopus citations

Original language	English (US)
Pages (from-to)	e236-e239
Journal	Haematologica
Volume	104
Issue number	6
DOIs	https://doi.org/10.3324/haematol.2018.208082
State	Published - 2019

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.2018.208082

Cite this

Patnaik, M. M., Pophali, P. A., Lasho, T. L., Finke, C. M., Horna, P., Ketterling, R. P., Gangat, N., Mangaonkar, A. A., Pardanani, A., & Tefferi, A. (2019). Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation. Haematologica, 104(6), e236-e239. https://doi.org/10.3324/haematol.2018.208082

@article{7d88ab9d38b1432ba34b2d6b52045313,

title = "Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation",

author = "Patnaik, {Mrinal M.} and Pophali, {Prateek A.} and Lasho, {Terra L.} and Finke, {Christy M.} and Pedro Horna and Ketterling, {Rhett P.} and Naseema Gangat and Mangaonkar, {Abhishek A.} and Animesh Pardanani and Ayalew Tefferi",

note = "Funding Information: 1Division of Hematology, Department of Medicine;2Division of Hematopathology, Department of Laboratory Medicine and Pathology and 3Division of Cytogenetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA Funding: this current publication is supported in part by grants from the The Henry J. Predolin Foundation for Research in Leukemia, Mayo Clinic, Rochester, MN, USA. This publication was supported by CTSA Grant Number KL2 TR000136 from the National Center for Advancing Translational Science (NCATS). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Funding Information: This current publication is supported in part by grants from the The Henry J. Predolin Foundation for Research in Leukemia, Mayo Clinic, Rochester, MN, USA. This publication was supported by CTSA Grant Number KL2 TR000136 from the National Center for Advancing Translational Science (NCATS). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.",

year = "2019",

doi = "10.3324/haematol.2018.208082",

language = "English (US)",

volume = "104",

pages = "e236--e239",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "6",

}

TY - JOUR

T1 - Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation

AU - Patnaik, Mrinal M.

AU - Pophali, Prateek A.

AU - Lasho, Terra L.

AU - Finke, Christy M.

AU - Horna, Pedro

AU - Ketterling, Rhett P.

AU - Gangat, Naseema

AU - Mangaonkar, Abhishek A.

AU - Pardanani, Animesh

AU - Tefferi, Ayalew

N1 - Funding Information: 1Division of Hematology, Department of Medicine;2Division of Hematopathology, Department of Laboratory Medicine and Pathology and 3Division of Cytogenetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA Funding: this current publication is supported in part by grants from the The Henry J. Predolin Foundation for Research in Leukemia, Mayo Clinic, Rochester, MN, USA. This publication was supported by CTSA Grant Number KL2 TR000136 from the National Center for Advancing Translational Science (NCATS). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Funding Information: This current publication is supported in part by grants from the The Henry J. Predolin Foundation for Research in Leukemia, Mayo Clinic, Rochester, MN, USA. This publication was supported by CTSA Grant Number KL2 TR000136 from the National Center for Advancing Translational Science (NCATS). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

PY - 2019

Y1 - 2019

UR - http://www.scopus.com/inward/record.url?scp=85066943143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066943143&partnerID=8YFLogxK

U2 - 10.3324/haematol.2018.208082

DO - 10.3324/haematol.2018.208082

M3 - Letter

C2 - 30606787

AN - SCOPUS:85066943143

SN - 0390-6078

VL - 104

SP - e236-e239

JO - Haematologica

JF - Haematologica

IS - 6

ER -

Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this